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Background: Magnetic nanoparticles (MNPs) have been a
subject of great interest in recent years due to their potential
biomedical applications as carriers for drug delivery, AmongMNPs,
superparamagneticmagnetite (Fe3 O4)hasbeenparticularly attrac-
tive due to its unique magnetic properties and biocompatibility
Thus we have developed the MNPs drug delivery carrier against
visceral leishmania.
Methods & Materials: The functionalization of Fe3O4 nanopar-
ticles has been done with dendrimer and glycine was carried out
in situ during co-precipitation of Fe 2+ and Fe 3+ ions in basic
medium. The terminal amino acid on the shell of the magnetic
nanocarriers allows us to create functionalized exteriors with high
densities of organic moieties (both amine and carboxyl) for encap-
sulation of drug molecules. The drug-loading efﬁciency of the
nanocarriers is investigated using amphoterecin B as a model drug
to evaluate their potential as a carrier system.
Results: Results andhigh loading afﬁnity of nanocarriers for
antileishmanial drug, their sustained release proﬁle and during
in vitro study, the mean 0.0801±0.0251 of extracellular pro-
mastigote of amphoterecin B is signiﬁcantly higher than MNPs
encapsulated amphoterecin B 0.1129±0.01499.
Conclusion: Study signiﬁes that there is an increased contact
surface area of the drug and signiﬁcant reduction in size, improved
its efﬁcacy than that of amphotericin B against visceral leishmania
and invitro study also showinghigh afﬁnity at lowdose,Further this
nanoformulations will be also good candidate as drug carriers for
other infectious disease.
http://dx.doi.org/10.1016/j.ijid.2014.03.746
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Background: Dihydroartemisinin piperaquine is increasingly
recommended for antimalarial treatment; however concerns have
been raised over its potential under dosing in children.The objec-
tives of this study was to investigate the inﬂuence of different
dosing schedules on Dihydroartemisinin piperaquine efﬁcacy
Methods & Materials: A three-day treatment was performed in
subjects weighting at least 5.5 kg presenting with a malaria con-
ﬁrmed by parasitaemia ≥ 2000/l. Patients were allocated into
one of different regimens dose according to bodyweight range.The
primary endpoint was the PCR adjusted risk of P. falciparum
recrudescence at the end of study. Secondary endpoints included
the new infections, parasitological clearance and gametocytemia.
Data were pooled using a standardized methodology. Risk factors
for parasite recrudescence were identiﬁed.
Results: 100 patients were included in the study. The overall
cure rates after correcting for reinfection by parasite genotyping
was 97.2% at day 28. In under 5 years children it was 93.8%.The
median dose administered was 6.3mg/kg for Dihydroartemisine,
and 50.3mg/kg for Piperaquine. Overall, 22.5% of patients received
Dihydroartemisinin and 23.7% received Piperaquine below WHO
recommended doses. Under ﬁve years childrenwere at the greatest
risk of being exposed to doses of Dihydroartemisinin <6mg/kg and
Piperaquine<48mg/kg, the lower limits recommended by WHO
compared to infants younger than 1 year and Children of 5 to 14
years.
Concerning Early Parasitological Response the overall para-
sitemia rate decreased from 53.2%on day 1 to 12.1%on day 2 and
1.7% on day 3. It was higher in children<5 years compared to
older children andadults. Concerning Late Parasitological Response
11.8% patients had recurrent parasitemia of whom 2.8%, conﬁrmed
by PCR as true recrudescence.Six risk factors were associated with
recrudescence fby day 28: Piperaquine dose, age, body weight,
gametocytemia and haemoglobin.
Conclusion: Dihydroartemisinin piperaquine had demon-
strated an excellent efﬁcacy however young children were
vulnerable to inadequate dose of Piperaquine, associated with
recrudesceence and gametocytemia. These data suggest further
studies for conﬁrming that increasing the dose of Dihy-
droartemisinin and Piperquine is likely to improve the cure rate
in young children and increase gametocytemia.
http://dx.doi.org/10.1016/j.ijid.2014.03.747
